Hsbc Holdings PLC Invests $912,000 in Masimo Co. (NASDAQ:MASI)

Hsbc Holdings PLC bought a new stake in shares of Masimo Co. (NASDAQ:MASI - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 5,494 shares of the medical equipment provider's stock, valued at approximately $912,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. FMR LLC increased its holdings in shares of Masimo by 19.8% during the fourth quarter. FMR LLC now owns 8,097,454 shares of the medical equipment provider's stock valued at $1,338,509,000 after acquiring an additional 1,340,836 shares in the last quarter. Vanguard Group Inc. increased its stake in Masimo by 1.5% during the 4th quarter. Vanguard Group Inc. now owns 4,586,702 shares of the medical equipment provider's stock valued at $758,182,000 after purchasing an additional 66,215 shares in the last quarter. Capital Research Global Investors raised its holdings in shares of Masimo by 80.5% in the fourth quarter. Capital Research Global Investors now owns 2,454,975 shares of the medical equipment provider's stock worth $405,807,000 after buying an additional 1,094,647 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its stake in shares of Masimo by 119.0% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 1,735,167 shares of the medical equipment provider's stock worth $286,823,000 after buying an additional 943,001 shares during the period. Finally, Alliancebernstein L.P. grew its holdings in shares of Masimo by 1,276.9% during the fourth quarter. Alliancebernstein L.P. now owns 947,391 shares of the medical equipment provider's stock valued at $156,604,000 after buying an additional 878,587 shares during the last quarter. 85.96% of the stock is currently owned by hedge funds and other institutional investors.

Masimo Stock Up 1.7 %

Shares of MASI opened at $166.42 on Monday. The company has a market capitalization of $8.99 billion, a price-to-earnings ratio of 114.77 and a beta of 1.28. Masimo Co. has a 52 week low of $101.61 and a 52 week high of $194.88. The stock's 50-day moving average price is $164.74 and its 200-day moving average price is $166.44. The company has a quick ratio of 1.11, a current ratio of 2.01 and a debt-to-equity ratio of 0.50.

Masimo (NASDAQ:MASI - Get Free Report) last released its quarterly earnings data on Tuesday, February 25th. The medical equipment provider reported $1.80 EPS for the quarter, topping the consensus estimate of $1.42 by $0.38. The business had revenue of $600.70 million for the quarter, compared to analyst estimates of $593.35 million. Masimo had a return on equity of 14.98% and a net margin of 3.85%. On average, sell-side analysts predict that Masimo Co. will post 4.1 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. Piper Sandler raised their target price on Masimo from $210.00 to $215.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 26th. Needham & Company LLC restated a "hold" rating on shares of Masimo in a research note on Thursday, April 10th. Finally, Wells Fargo & Company upped their target price on Masimo from $193.00 to $205.00 and gave the company an "overweight" rating in a research report on Wednesday, February 26th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $194.80.

Insider Activity at Masimo

In other Masimo news, COO Bilal Muhsin sold 30,000 shares of the firm's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $167.49, for a total value of $5,024,700.00. Following the sale, the chief operating officer now directly owns 24,172 shares of the company's stock, valued at approximately $4,048,568.28. This trade represents a 55.38 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Craig B. Reynolds sold 2,053 shares of the company's stock in a transaction that occurred on Friday, March 14th. The stock was sold at an average price of $166.13, for a total value of $341,064.89. Following the transaction, the director now directly owns 16,581 shares of the company's stock, valued at approximately $2,754,601.53. The trade was a 11.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 9.70% of the stock is owned by company insiders.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.

Want to see what other hedge funds are holding MASI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Masimo Co. (NASDAQ:MASI - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.